BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 20691326)

  • 1. Valsartan inefficacy or ill-effects of concomitant medications!
    Bangalore S; Messerli FH
    Am J Cardiol; 2010 Aug; 106(4):602-3. PubMed ID: 20691326
    [No Abstract]   [Full Text] [Related]  

  • 2. Aliskiren/valsartan (Valturna) for hypertension.
    Med Lett Drugs Ther; 2009 Nov; 51(1326):94-5. PubMed ID: 20224524
    [No Abstract]   [Full Text] [Related]  

  • 3. Angiotensin II receptor antagonists and heart failure: angiotensin-converting-enzyme inhibitors remain the first-line option.
    Prescrire Int; 2005 Oct; 14(79):180-6. PubMed ID: 16285075
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Proteinuria, chronic kidney disease, and the effect of an angiotensin receptor blocker in addition to an angiotensin-converting enzyme inhibitor in patients with moderate to severe heart failure.
    Anand IS; Bishu K; Rector TS; Ishani A; Kuskowski MA; Cohn JN
    Circulation; 2009 Oct; 120(16):1577-84. PubMed ID: 19805651
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapeutic implications of high-dose angiotensin receptor blocker monotherapy in mild-to-moderate hypertensive patients.
    Yano Y; Kario K
    Hypertens Res; 2010 Oct; 33(10):981-3. PubMed ID: 20720555
    [No Abstract]   [Full Text] [Related]  

  • 6. Two amlodipine/ARB combinations for hypertension.
    Med Lett Drugs Ther; 2007 Dec; 49(1276):101-2. PubMed ID: 18084152
    [No Abstract]   [Full Text] [Related]  

  • 7. [Fetal toxicity of angiotensin-II-receptor inhibitors. Case report].
    Roger N; Popovic I; Madelenat P; Mahieu-Caputo D
    Gynecol Obstet Fertil; 2007 Jun; 35(6):556-60. PubMed ID: 17544313
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Valsartan in chronic heart failure.
    Ripley TL
    Ann Pharmacother; 2005 Mar; 39(3):460-9. PubMed ID: 15687480
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Amlodipine/valsartan single-pill combination: a review of its use in the management of hypertension.
    Frampton JE; Scott LJ
    Am J Cardiovasc Drugs; 2009; 9(5):309-30. PubMed ID: 19791840
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Valsartan, captopril, or both in myocardial infarction.
    Jorde UP
    N Engl J Med; 2004 Feb; 350(9):943-5; author reply 943-5. PubMed ID: 14988936
    [No Abstract]   [Full Text] [Related]  

  • 11. Valsartan, captopril, or both in myocardial infarction.
    Moshenyat R; Kupfer Y; Tessler S
    N Engl J Med; 2004 Feb; 350(9):943-5; author reply 943-5. PubMed ID: 14988935
    [No Abstract]   [Full Text] [Related]  

  • 12. Effects of the angiotensin II type 1 receptor antagonist valsartan on the expression of superoxide dismutase in hypertensive patients.
    Yang HY; Kao PF; Chen TH; Tomlinson B; Ko WC; Chan P
    J Clin Pharmacol; 2007 Mar; 47(3):397-403. PubMed ID: 17322151
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Preventing end-organ damage in hypertension. What is the significance of the VALUE Study for general practice?].
    Zidek W
    MMW Fortschr Med; 2004 Jul; 146(27-28):41. PubMed ID: 15526662
    [No Abstract]   [Full Text] [Related]  

  • 14. [Scientific evidence--applied in routine general practice. Successful decrease in pressure and risk].
    MMW Fortschr Med; 2006 May; 148(18):42-3. PubMed ID: 16736689
    [No Abstract]   [Full Text] [Related]  

  • 15. Exforge HCT.
    Med Lett Drugs Ther; 2009 Jun; 51(1314):47. PubMed ID: 19528888
    [No Abstract]   [Full Text] [Related]  

  • 16. Two multicenter, 8-week, randomized, double-blind, placebo-controlled, parallel-group studies evaluating the efficacy and tolerability of amlodipine and valsartan in combination and as monotherapy in adult patients with mild to moderate essential hypertension.
    Philipp T; Smith TR; Glazer R; Wernsing M; Yen J; Jin J; Schneider H; Pospiech R
    Clin Ther; 2007 Apr; 29(4):563-80. PubMed ID: 17617280
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Valsartan-induced angioedema in a patient on angiotensin-converting enzyme inhibitor for years: case report and literature review.
    Kalra A; Cooley C; Palaniswamy C; Kalra A; Zanotti-Cavazzoni SL
    Am J Ther; 2012 Nov; 19(6):e189-92. PubMed ID: 20838200
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Morbidity, mortality, physiologic and functional parameters in elderly and non-elderly patients in the Valsartan Heart Failure Trial (Val-HeFT).
    Baruch L; Glazer RD; Aknay N; Vanhaecke J; Heywood JT; Anand I; Krum H; Hester A; Cohn JN
    Am Heart J; 2004 Dec; 148(6):951-7. PubMed ID: 15632877
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Renin-angiotensin system blockade in the treatment of heart failure and the role of valsartan in this treatment.
    Kılıçkıran Avcı B; İkitimur B; Karadağ B; Öngen Z
    Anadolu Kardiyol Derg; 2014 Dec; 14 Suppl 2():S1-8. PubMed ID: 25604202
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New clinical investigations with selective angiotensin II receptor blocker therapy in diabetes and renal disease.
    Ruilope LM
    J Renin Angiotensin Aldosterone Syst; 2000 Jun; 1(2 Suppl):S29-31. PubMed ID: 17199217
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.